- 掃描二維碼關(guān)注儀器無(wú)憂網(wǎng)微信公眾平臺(tái)
- 您可以獲得:
- 1.更高效的咨詢方式
- 2.更便利的瀏覽體驗(yàn)
- 3.實(shí)時(shí)的動(dòng)態(tài)信息獲取
- 儀器無(wú)憂網(wǎng)
- 服務(wù)中心
Xcellerex
美國(guó)Xcellerex www.xcellerex.com
總部位于馬薩諸塞州的Xcellerex擁有135名雇員,其營(yíng)收大約為5000萬(wàn)美元。該公司獲得的風(fēng)險(xiǎn)資本投資包括Kleiner Perkins Caufield & Byers、VantagePoint Venture Partners和SCG Capital。
2012年GE Healthcare收購(gòu)Xcellerex
Xcellerex is revolutionizing the way biomolecules are developed, manufactured and commercialized.
Xcellerex is built around a unique biomanufacturing platform that features the innovative application of single-use component technology. The Xcellerex platform transforms biomanufacturing economics by enabling:
Faster deployment of new manufacturing capacity: 12-18 months vs. 3-5 years.
Reduced capital investment: Typical savings of 50% to 70% compared to conventional approaches.
Unmatched flexibility: Modular microenvironment approach enables fast, low-cost redeployment for multi-drug production.
Xcellerex offers a suite of world-class products and services to support the adoption of its platform. These include the XDR line of single-use bioreactors, PDMax® high-throughput process development and optimization services, and proven GMP manufacturing operated by an experienced CMC team. The company also actively seeks creative partnerships to facilitate access to the platform.